Immix Biopharma prices USD 150 million follow-on stock offering at USD 8.94/share

Immix Biopharma, Inc.

Immix Biopharma, Inc.

IMMX

0.00
  • Immix Biopharma priced an underwritten follow-on offering of 16,778,524 common shares at USD 8.94 each, targeting USD 150 million in gross proceeds.
  • Closing is expected around May 22, 2026, subject to customary conditions.
  • Net proceeds are earmarked for NXC-201 development, working capital, general corporate purposes; cash runway projected into mid-2028.
  • Morgan Stanley is lead book-runner; BofA Securities is also a book-running manager.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605210630PRIMZONEFULLFEED9724614) on May 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.